Skip to main content

Impact of adopting minimum inhibitory concentration as the determinant of susceptibility to cephalosporins and carbapenems in multi-drug resistant Enterobacteriaceae

European Journal of Clinical Microbiology & Infectious Diseases volume 31, pages 975–980 (2012)Cite this article

Abstract

The Clinical and Laboratory Standards Institute has recommended that Enterobacteriaceae susceptibility to most cephalosporins and carbapenems be reported according to minimum inhibitory concentration (MIC) alone. We analyzed our record of multi-drug resistant Enterobacteriaceae to assess the impact of these changes. We compared susceptibilities of ceftriaxone-resistant Enterobacteriaceae when using the 2009 and new 2010 MIC standards. Vitek2® (BioMerieux), was used to assess the changes in susceptibility. Klebsiella pneumoniae, Proteus sp., and Escherichia coli were the major species from urine, sputum, blood, and other sterile sites. The new breakpoint for cephalosporins increased resistance in E. coli and P. mirabilis. Many Proteus categorized as resistant by extended-spectrum beta-lactamase (ESBL) detection or inferred resistance have MICs to ceftriaxone ≤1 mcg/ml. New carbapenem breakpoints increased resistant Klebsiella pneumoniae and Proteus mirabilis. The increased ceftriaxone resistance from lowering breakpoints was almost balanced by the loss of resistance in ESBL isolates with MICs ≤1 mcg/ml. MIC-based susceptibility for multi-drug resistant Enterobacteriaceae increases the number of resistant isolates. Inferring mechanisms of resistance has a disproportionate effect on the susceptibility of Proteus mirabilis to cephalosporins, and the MIC-based standard has an almost equivalent but opposite effect on Proteus mirabilis susceptibility to carbapenems.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. CLSI (2010) Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI document M100-20

  2. CLSI (2010) Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI document M100-20u

  3. Schwaber MJ, Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwartz D, Carmeli Y (2006) Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in Enterobacter spp. J Clin Microbiol 44(1):241–243

    PubMed  Article  CAS  Google Scholar 

  4. Thomson KS (2010) Extended-spectrum-beta-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 48(4):1019–1025

    PubMed  Article  CAS  Google Scholar 

  5. Sanders CC, Peyret M, Moland ES, Shubert C, Thomson KS, Boeufgras JM, Sanders WE Jr (2000) Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 38(2):570–574

    PubMed  Google Scholar 

  6. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA (2010) Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 54(1):109–115

    PubMed  Article  CAS  Google Scholar 

  7. Dooley SW, Jarvis WR, Martone WJ, Snider DE Jr (1992) Multidrug-resistant tuberculosis. Ann Intern Med 117(3):257–259

    PubMed  CAS  Google Scholar 

  8. File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D (2010) Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51(12):1395–1405

    PubMed  Article  CAS  Google Scholar 

  9. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J (2010) Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007–2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 54(7):3031–3034

    PubMed  Article  CAS  Google Scholar 

  10. Chin BS, Seo WY, Paterson DL, Potoski BA, Peleg AY (2009) Cefepime MIC breakpoint resettlement in gram-negative bacteria. Antimicrob Agents Chemother 53(1):337–338

    PubMed  Article  CAS  Google Scholar 

  11. Song W, Moland ES, Hanson ND, Lewis JS, Jorgensen JH, Thomson KS (2005) Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 43(9):4891–4894

    PubMed  Article  Google Scholar 

  12. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A (2007) Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45(6):753–760

    PubMed  Article  CAS  Google Scholar 

  13. Mataseje LF, Boyd DA, Willey BM, Prayitno N, Kreiswirth N, Gelosia A, Poutanen SM, Low DE, Jenkins SG, Katz K, Mulvey MR (2011) Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring blaKPC from New York City and Toronto. J Antimicrob Chemother 66(6):1273–1277

    Google Scholar 

  14. Kohner PC, Robberts FJ, Cockerill FR 3rd, Patel R (2009) Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol 47(8):2419–2425

    PubMed  Article  CAS  Google Scholar 

  15. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J (1987) Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 2(8554):302–306

    PubMed  Article  CAS  Google Scholar 

  16. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K (1989) Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 33(9):1451–1456

    PubMed  CAS  Google Scholar 

  17. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC Jr, Jacoby GA (1990) Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 34(11):2193–2199

    PubMed  CAS  Google Scholar 

  18. Smith CE, Tillman BS, Howell AW, Longfield RN, Jorgensen JH (1990) Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother 34(6):1290–1293

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    M. Parta

  2. Baylor College of Medicine, 1709 Dryden Road, Suite 6.12, MS: BCM 620,625, Houston, TX, 77030, USA

    M. Parta

Authors
  1. M. Parta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Parta.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Parta, M. Impact of adopting minimum inhibitory concentration as the determinant of susceptibility to cephalosporins and carbapenems in multi-drug resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 31, 975–980 (2012). https://doi.org/10.1007/s10096-011-1394-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1394-8

Keywords

  • Minimum Inhibitory Concentration
  • Cephalosporin
  • Ceftriaxone
  • Imipenem
  • Cefepime